News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medicis Licenses Proprietary Peptide Technology From Ansata Therapeutics, Inc.



10/19/2005 5:12:28 PM

SCOTTSDALE, Ariz. and VILLAGE OF LA JOLLA, Calif.--(BUSINESS WIRE)--Dec. 14, 2004--Medicis (NYSE:MRX) and Ansata Therapeutics, Inc. ("Ansata") today announced they have entered into an exclusive development and license agreement and other ancillary agreements. The development and license agreement grants Medicis the exclusive, worldwide rights to Ansata's early-stage, proprietary antimicrobial peptide technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES